TEX46 and cancer: To assess the potential role of TEX and CD3(+) sEV in plasma of cancer patients as biomarkers able to predict patients’ response to oncological therapies, we serially monitored molecular profiles of these sEV subsets in a small cohort of HNSCC patients with recurrent/metastatic disease treated with cetuximab, IMRT and ipilimumab in a phase I clinical trial (NCT01935921) [80].